
CDC data shows Candida auris cases declining from 2023 highs but drug resistance worsening, with over 95% of samples resistant to first-line fluconazole.
The CDC reported 3,437 Candida auris cases through July 25, down from 4,290 a year earlier. California led with 873 cases, followed by Texas at 433 and Tennessee at 283. The rate of new infections has slowed since 2022, the agency said, but resistance to frontline treatments is climbing.
A CDC study of 8,033 samples collected in 2022-2023 found over 95% resistant to fluconazole, the standard first-line antifungal. About 15% resisted amphotericin B, and 1% resisted echinocandins, the last-resort class. Fewer than 1% were resistant to all three drug classes, the agency said.
The fungus spreads in healthcare settings through contact with contaminated surfaces or infected patients. It can survive on doorknobs, bedrails, and shared equipment for long periods. Healthy people face little risk, the CDC said; most infections occur in immunocompromised patients already hospitalized for other conditions.
Mortality estimates range from 30% to 60%, but the CDC cautioned that underlying illnesses make it hard to isolate the fungus's role in deaths. The WHO classifies C. auris as a critical priority fungal pathogen.
First identified in 2009 in Japan, the strain was discovered earlier in Korean samples from 1996. The slowing case growth does not mean transmission is accelerating, the CDC noted – the base is still expanding, just at a slower pace than the peak years.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.